CAMBRIDGE, Mass., Nov. 7, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the quarter ended September 30, 2012.
For the third quarter of 2012, the company reported a net loss of $25.8 million, or ($0.51) per diluted share, compared to a net income of $60.3 million, or $1.18 per diluted share, for the same period in 2011. At September 30, 2012, the company had cash, cash equivalents, and marketable securities of $361.8 million.
"Royalty revenues from enoxaparin sodium injection in the third quarter were disappointing and reflected the market realities of a more competitive multi-player dynamic," said Craig Wheeler, President and Chief Executive Officer of Momenta Pharmaceuticals. "We continue to invest in our promising development pipeline of complex generics, biosimilars and novel drugs.
"Today, I am pleased to announce that Momenta has made significant progress in demonstrating that sialylation of Fc enhances anti-inflammatory effects in a preclinical model. This work is consistent with the findings previously published by Jeffrey Ravetch, M.D., Ph.D., of The Rockefeller University. This is an exciting example of how we are applying the tools and methods used to develop generics and biosimilars to novel drug development. We look forward to optimizing a drug candidate that we can take into the clinic," Mr. Wheeler concluded.
Third Quarter Events
Complex Generics Program:
Enoxaparin sodium injection
M356, generic version of Copaxone® (glatiramer acetate injection)
Follow-on Biologics Program:
Novel Drug Program:
M402, novel oncology candidate
Sialylation research program
Third Quarter 2012 Financial Results
Total collaboration revenue for the third quarter of 2012 was $5.1 million (including enoxaparin product revenue of $2.6 million), compared to $87.9 million (including enoxaparin product revenue of $84.7 million) for the same period in 2011. Sandoz reported third quarter 2012 enoxaparin net sales of $34 million, compared with $259 million for the third quarter 2011. The significant decrease in enoxaparin product revenue reflects competitive market pressure experienced during the third quarter and includes the impact of resulting pricing adjustments recorded by Sandoz.
Collaborative research and development revenue for the third quarter of 2012 was $2.5 million, which included $1.2 million expense reimbursement from Sandoz under the enoxaparin and generic Copaxone collaborations, $0.5 million amortization of the equity premium received from the 2006 Sandoz collaboration, and $0.8 million amortization of the $33 million payment paid by Baxter.
Research and development expenses for the third quarter of 2012 were $20.2 million, compared to $16.3 million for the same period in 2011. The increase of $3.9 million was primarily due to increases of $3.0 million in personnel and facilities-related expenses, $0.5 million in laboratory expenses, and $0.4 million in M402 clinical development costs.
General and administrative expenses for the quarter ended September 30, 2012 were $11.0 million, compared with $11.5 million for the same period in 2011. Excluding the royalty payable to MIT on enoxaparin product revenues which decreased by $2.9 million, all other general and administrative expenses increased by $2.4 million. The increase was primarily due to an increase of $1.1 million in legal expenses, largely related to enoxaparin patent litigation, an increase of $0.9 million in personnel and facilities-related expenses and an increase in stock-based compensation expense of $0.2 million.
At September 30, 2012, Momenta had $361.8 million in cash, cash equivalents and marketable securities. This cash position excludes restricted cash of $17.5 million, which serves as collateral for a security bond related to enoxaparin legal proceedings, and $2.5 million of cash that is restricted in connection with a facility lease letter of credit.
Momenta confirmed its guidance provided on February 9, 2012 for total operating expenses, excluding stock-based compensation and net of related collaborative revenues, of approximately $22 to $28 million per quarter for 2012. For the third quarter of 2012, operating expenses ($31.2 million) less stock compensation ($3.5 million) less collaborative expense reimbursements ($1.2 million) totaled $26.5 million.
Today, Momenta provided guidance for 2013 total operating expenses, excluding stock-based compensation and net of collaborative revenues, of approximately $30 million per quarter. For 2013, Momenta is projecting that its net cash usage will average approximately $20 to $24 million per quarter for a total operating cash usage of approximately $90 million.
Conference Call Information
Management will host a conference call and webcast today, November 7, 2012 at 10:00 am ET to discuss these results and provide an update on the company. A live webcast of the conference call may be accessed on the "Investors" section of the company's website, www.momentapharma.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call and will be available through November 21, 2012.
To access the call you may also dial (877) 224-9084 (domestic) or (720) 545-0022(international) prior to the scheduled conference call time and provide the access code 49562998. A replay of the call will be available approximately two hours after the conclusion of the call and will be accessible through November 14, 2012. To access the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and provide the access code 49562998.
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, follow-on biologics and to the discovery and development of novel drugs.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Forward Looking Statements
Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, the Company's revenue, expenses, including total operating expenses for 2012 and 2013 total operating expense and cash usage, and other results of operations, including the quarter ended September 30, 2012, our expected product development milestones and timing for clinical and non-clinical results, our plans for future research and development investment, and our other product development plans and expectations constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "hope," "target," "project," "goals," "potential," "predict," "might," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors referred to in the company's Quarterly Report on Form 10-Q for quarter ended June 30, 2012 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Momenta from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Momenta is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
|MOMENTA PHARMACEUTICALS, INC.|
|Unaudited, Condensed Consolidated Balance Sheets|
|Cash and marketable securities||$ 361,818||$ 348,438|
|Short-term and long-term restricted cash||19,971||17,500|
|Total assets||$ 422,599||$ 420,909|
|Liabilities and Stockholders' Equity|
|Current liabilities||$ 20,194||$ 16,028|
|Deferred revenue, net of current portion||27,631||1,608|
|Total liabilities and stockholders' equity||$ 422,599||$ 420,909|
|MOMENTA PHARMACEUTICALS, INC.|
|Unaudited Condensed Statements of Comprehensive (Loss) Income|
|(in thousands, except per share amounts)|
Three Months Ended
Nine Months Ended
|Product revenues||$ 2,579||$ 84,717||$ 43,960||$ 244,325|
|Research and development revenues||2,523||3,228||7,233||9,288|
|Total collaboration revenues||5,102||87,945||51,193||253,613|
|Research and development*||20,233||16,307||58,805||43,418|
|General and administrative*||10,999||11,480||34,309||28,995|
|Total operating expenses||31,232||27,787||93,114||72,413|
|Operating (loss) income||(26,130)||60,158||(41,921)||181,200|
|Other income (expense):|
|Total other income||308||180||950||409|
|Net (loss) income||$ 25,822)||$60,338||$ (40,971)||$ 181,609|
|Net (loss) income per share:|
|Basic||$ (0.51)||$ 1.21||$ (0.81)||$ 3.65|
|Diluted||$ (0.51)||$ 1.18||$ (0.81)||$ 3.58|
|Weighted average shares outstanding:|
|Comprehensive (loss) income||$ (25,637)||$ 60,130||$ (40,719)||$ 181,477|
*Includes the following share-based compensation expense:
|Research and development||$ 1,530||$ 1,339||$ 4,317||$ 3,551|
|General and administrative||$ 2,019||$ 1,778||$ 5,943||$ 4,465|
Lora Pike Momenta Pharmaceuticals, Inc. (617) 395-5189